In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
Ultra Protection: Epidermal protection, repair UV damage No need to add auxiliary absorption products, comes with EUF ecological super energy to help absorption
ERS occurs when the folding capacity of the ER is overwhelmed, leading to an accumulation of misfolded or unfolded proteins
Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y
On a per-serving basis, that's roughly 30% cheaper than Double Wood, our budget pick
CPT codes 92628-92642 were reviewed at the April 2024 RUC HCPAC meeting for CY 2026